Navigation Links
Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
Date:5/26/2010

ication (MAA) for DUEXA in the European Union through the Decentralized Procedure in the second half of 2010.

About DUEXA

DUEXA is a novel, proprietary fixed-dose tablet combining the one of the world's most prescribed NSAIDs, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill.  Ibuprofen has proven anti-inflammatory and analgesic properties, whereas famotidine reduces the stomach acid secretion that can cause gastric and duodenal ulceration.   By combining ibuprofen and famotidine into a single product, it is believed that ibuprofen's gastrointestinal safety profile will be improved without altering its ability to reduce pain and inflammation.

About the Arthritis and Pain Market

According to the Arthritis Foundation, arthritis affects 46 million people in the U.S. and costs the U.S. economy $128 billion annually.  According to a study by the Centers for Disease Control and Prevention (CDC) for the National Arthritis Data Workgroup, due to the increasing aging population, arthritis is projected to increase by 40 percent in the next two decades.  The CDC estimates that 67 million people in the U.S. will be affected by arthritis by 2030.  Additionally, chronic pain affects an estimated 86 million American adults. NSAIDs are among the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced.  Because the prostaglandins that protect the stomach are reduced, NSAIDs often cause ulcers in the stomach. NSAID-induced GI toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations annually in the U
'/>"/>

SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
2. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
6. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
7. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
8. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
9. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... Dilon expands its portfolio of breast imaging solutions ... Mammography Information System technology by KLAS for three ... loyalty are the foundation of PenRad,s success. Together ... and an information management system that significantly improves ...
... Hurricane Irene came rushing up the East Coast as a ... United States, many states in the Northeast began to worry. The ... hurricanes. Coastal towns from New Jersey all the way up to ... City was one that took steps that had not been seen ...
Cached Medicine Technology:Dilon Diagnostics® Partners With PenRad® 2Dilon Diagnostics® Partners With PenRad® 3Hospitals Evacuated in Preparation for Hurricane Irene with Aid of Pulse Oximeter 2
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to ... added her voice to those calling for a ban ... in Denver, Debra Valverde was diagnosed with leiomyosarcoma following ... morcellator. Within a year of her diagnosis, the aggressive ...
(Date:7/30/2014)... Hospitals continually face the challenge of ... their practitioners provide. During a recent AllMed webinar, ... importance of establishing effective peer review practitioner evaluation ... of care. , With regard to best ... on setting performance expectations, conducting regular evaluations, maintaining ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... China Chitosan Industry” is a professional and ... market. The report provides basic Chitosan information, ... chain structure as well as industry overview. ... China’s domestic market as well as global ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... the many sub-groups of cells jockeying for supremacy within ... those that can proliferate the fastest, researchers at Dana-Farber ... advance online publication of the journal Nature . ... of cancer with precision medicines, the study authors explained: ... driving the tumor,s growth and metastasis and select drugs ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3
... safer glucocorticoid drugs , Glucocorticoid drugs are ... allergic reactions, asthma, and some forms of cancer, and ... their potent antiinflammatory and immunosuppressive properties. However, their long-term ... blood levels of glucose, fatty liver, and type 2 ...
... , This release is available in French ... and the brain appear to be even more closely connected ... apparently not confined to the heart, but also affect the ... the level of the brainstem, which leads to insomnia, notably ...
... be the victim of a snakebite, the best thing you ... possible, according to a new review article from the ... Current medical treatments, including new medications and surgery, if necessary, ... do on your own. , "Previous generations of antivenin medications ...
... risk of prostate cancer, a new study published today in the ... led by The University of Warwick and The Institute of Cancer ... ring finger were one third less likely to develop the disease ... show that relative finger length could be used as a simple ...
... 2010 Elsevier, the leading publisher of scientific, technical ... availability of Case Reviews Online, an online edition of ... for board review. The Case Reviews Online ... board preparation needs. Detailed cases, including 4-10 images ...
... Eating a diet rich in omega-3 fatty acids appears to ... known as age-related macular degeneration (AMD), a new analysis indicates. ... and shellfish may protect against advanced AMD," study lead author ... Hopkins School of Medicine in Baltimore, said in a news ...
Cached Medicine News:Health News:JCI online early table of contents: Dec. 1, 2010 2Health News:JCI online early table of contents: Dec. 1, 2010 3Health News:JCI online early table of contents: Dec. 1, 2010 4Health News:JCI online early table of contents: Dec. 1, 2010 5Health News:JCI online early table of contents: Dec. 1, 2010 6Health News:JCI online early table of contents: Dec. 1, 2010 7Health News:JCI online early table of contents: Dec. 1, 2010 8Health News:JCI online early table of contents: Dec. 1, 2010 9Health News:JCI online early table of contents: Dec. 1, 2010 10Health News:Insomnia after myocardial infarction 2Health News:What to do if you are bitten by a snake 2Health News:Finger length points to prostate cancer risk 2Health News:Elsevier launches innovative online radiology board review product 2Health News:Can Omega-3 Foods Prevent Eye Disease in Seniors? 2
... premium product for acne, XtremeClear, powered ... on a scalable multi-application platform. A ... acne, XtremeClear works fast, providing noticeable ... treatments. Uncompromising safety in each of ...
... SpaTouch was designed specifically to meet the varying ... is a simple to use, compact, dual application ... lucrative field of light based hair removal. SpaTouch ... is safe for use on nearly all face ...
... all of the benefits and functionality ... the additional feature of being able ... scanner for importing and storage of ... images. This additional feature allows for ...
Inquire...
Medicine Products: